首药控股(688197) - 2024 Q3 - 季度财报

Financial Performance - Total revenue for the third quarter was CNY 3,800,000, a decrease of 24% compared to the same period last year[2] - Net loss attributable to shareholders was CNY -57,125,459.15 for the quarter, with a year-to-date loss of CNY -159,978,134.87[2] - Total operating revenue for the first three quarters of 2024 was CNY 3.8 million, a decrease of 24% compared to CNY 5 million in the same period of 2023[16] - Net loss attributable to shareholders of the parent company was CNY -159.98 million, compared to a loss of CNY -136.05 million in the same period of 2023[18] - The total comprehensive loss for the period was CNY -159.98 million, compared to CNY -136.05 million in the same period last year[18] - The net loss for the first three quarters of 2024 was CNY 159,738,947.54, compared to a net loss of CNY 135,712,258.20 in the same period of 2023, reflecting a worsening of approximately 17.7%[25] - The company’s total comprehensive loss for the first three quarters of 2024 was CNY 159,738,947.54, compared to CNY 135,712,258.20 in the same period of 2023[25] Research and Development - Research and development expenses totaled CNY 56,942,225.08, representing an increase of 12.32% year-on-year[4] - The ratio of R&D expenses to total revenue increased by 1395.85 percentage points, indicating a significant focus on R&D initiatives[4] - The company is currently in the new drug development phase, which has led to increased R&D spending and a decline in profitability[8] - Research and development expenses rose to CNY 164.04 million, compared to CNY 146.05 million in the same period last year, reflecting a 12.3% increase[16] - The company incurred research and development expenses of CNY 167,952,758.80 in the first three quarters of 2024, compared to CNY 151,241,726.04 in the same period of 2023, indicating an increase of approximately 11%[24] Cash Flow and Liquidity - Cash flow from operating activities was CNY -47,094,611.37, with a year-to-date cash flow of CNY -144,235,376.10[2] - Operating cash flow for the first three quarters of 2024 was CNY 17,646,686.04, a decrease of 42.5% compared to CNY 30,564,755.34 in the same period of 2023[19] - Net cash flow from operating activities was -CNY 144,235,376.10, compared to -CNY 135,482,280.11 in the previous year, indicating a worsening cash flow situation[20] - The company reported cash inflow from investment activities of CNY 1,399,229,624.57, while cash outflow was CNY 1,697,827,898.31, resulting in a net cash outflow of -CNY 298,598,273.74 from investment activities[20] - The cash and cash equivalents at the end of the period were CNY 82,240,594.79, down from CNY 675,856,379.06 at the end of the same period in 2023[27] - The company's cash and cash equivalents decreased to RMB 83,350,249.11 from RMB 530,340,395.30 year-over-year, indicating a significant reduction in liquidity[12] Assets and Liabilities - Total assets at the end of the quarter were CNY 984,710,001.07, down 11.46% from the previous year[4] - Total liabilities increased to CNY 123.74 million, up from CNY 91.16 million in the previous year, marking a 35.7% increase[15] - Total current assets decreased from RMB 982,252,710.03 to RMB 844,541,306.48, reflecting a decline of approximately 14.0%[13] - The total assets decreased from RMB 1,112,111,011.82 to RMB 984,710,001.07, a decline of approximately 11.5%[13] - The total current liabilities increased to CNY 122,784,130.50 in Q3 2024 from CNY 96,982,040.45 in the previous year, indicating a rise of about 26.5%[23] - The company’s total equity decreased to CNY 862,117,999.73 from CNY 1,021,856,947.27 in the previous year[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 3,635, with the largest shareholder, Li Wenjun, holding 72,953,101 shares, representing 49.05% of the total[9] - The number of shares held by the top ten shareholders includes significant stakes from state-owned and private entities, with the top three shareholders holding a combined total of 85.59%[10] - The company has not reported any significant changes in shareholder relationships or agreements among the top shareholders[11]